Ginkgo Bioworks Holdings, Inc.
DNA- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001830214
In the last 90 days, Ginkgo Bioworks Holdings, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $359.2M in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $43.7K in total
- 3
- 13F holdersQ2 2026, +11 vs. previous quarter
- 183
- 13F valueReported value at the end of Q2 2026
- $359.2M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding DNA, Q2 2026
1 superinvestor reports holding Ginkgo Bioworks Holdings, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.1%
Ginkgo Bioworks Holdings, Inc.'s share of the portfolio
- Shares
- 3,577,128
- Value
- $35.4M
Latest insider trades
Open-market purchases and sales by Ginkgo Bioworks Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 (view filing)4:06 PM ET | Sep 15 | 1 day | Henry Christian ODirector | SSaleClass A Common Stock | −5.00K | $7.08 | −$35.4K | −20.6%19.3K after | |
| Aug 25, 2026 (view filing)5:01 PM ET | Aug 24 | 1 day | Coen Steven P.See remarks | SSaleClass A Common Stock | −330 | $6.98 | −$2.30K | −0.6%51.9K after | |
| Jul 20, 2026 (view filing)5:00 PM ET | Jul 17 | 3 days | Coen Steven P.See remarks | SSaleClass A Common Stock | −752 | $7.90 | −$5.94K | −1.4%51.4K after | |
| May 26, 2026 (view filing) | May 22 | 4 days | Coen Steven P.See remarks | SSaleClass A Common Stock | −307 | $8.33 | −$2.56K | −0.6%50.7K after | |
| Apr 20, 2026 (view filing) | Apr 17 | 3 days | Coen Steven P.See remarks | SSaleClass A Common Stock | −324 | $7.95 | −$2.58K | −0.6%50.3K after | |
| Apr 14, 2026 (view filing) | Apr 13 | 1 day | Coen Steven P.See remarks | SSaleClass A Common Stock | −33.2K | $6.41 | −$212.6K | −40.0%49.8K after | |
| Apr 13, 2026 (view filing) | Apr 10 | 3 days | Canton Barry10% Owner | SSaleClass A Common Stock | −124.7K | $6.43 | −$802.0K | −22.2%436.4K after | Duplicate filing |
| Apr 13, 2026 (view filing) | Apr 10 | 3 days | Shetty Reshma P.See remarks | SSaleClass A Common Stock | −124.7K | $6.43 | −$802.0K | −22.2%436.4K after | |
| Apr 10, 2026 (view filing) | Apr 8-9 | 2 days | Shetty Reshma P.See remarks | SSaleClass A Common Stock | −26.3K | $6.67 | −$175.1K | −7.2%338.6K after | 2 lotsDuplicate filing |
| Apr 10, 2026 (view filing) | Apr 8-9 | 2 days | Canton Barry10% Owner | SSaleClass A Common Stock | −26.3K | $6.67 | −$175.1K | −7.2%338.6K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Ginkgo Bioworks Holdings, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,282,903 | $42.4M | 0.00% | +640,556+17.6% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,577,128 | $35.4M | 0.10% | 00.0% | Unchanged |
| Erste Asset Management GmbH | 2,536,939 | $25.9M | 0.20% | +589,211+30.3% | Added |
| Baillie Gifford & Co | 2,391,649 | $23.7M | 0.02% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,087,293 | $20.7M | 0.00% | +172,865+9.0% | Added |
| Anchorage Capital Group, L.L.C. | 1,746,363 | $17.3M | 3.84% | 00.0% | Unchanged |
| Legal & General Group Plc | 1,669,419 | $16.5M | 0.00% | +7,832+0.5% | Added |
| State Street Corp | 1,472,370 | $14.6M | 0.00% | +125,711+9.3% | Added |
| Geode Capital Management, LLC | 1,222,016 | $12.1M | 0.00% | +212,654+21.1% | Added |
| Forbes J M & Co LLP | 999,911 | $9.91M | 0.78% | −28,480−2.8% | Reduced |